Summary
Cannot evaluate alignment because the AI response content is not provided in the audit input in a manner that maps claims to the FDA label text. The prompt includes a separate list of claims, but no actual AI-generated response text to audit.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is an inhibitor of HMG-CoA reductase; the enzyme converts HMG-CoA to mevalonate; Lipitor tablets contain 10, 20, 40, and 80 mg atorvastatin.
Label support present in DESCRIPTION and Mechanism of Action (12.1) and Dosage Forms and Strengths (3).
Unsupported Statements
Lipitor is a prescription medication developed by Pfizer.
No sponsor/developer information is included in the provided label sections.
Statins work by inhibiting the production of cholesterol in the liver.
While the label indicates liver is the principal site of action and atorvastatin inhibits HMG-CoA reductase and cholesterol synthesis in the liver (12.1), the specific phrasing 'statins work by inhibiting the production of cholesterol in the liver' is not directly stated as 'statins' generally in the provided excerpts (12.1/12.2 reference atorvastatin/atorvastatin-like statements).
Lipitor binds to the active site of HMG-CoA reductase and inhibits its activity.
The provided label excerpts describe selective competitive inhibition of HMG-CoA reductase but do not explicitly state 'binds to the active site.'
Lipitor has been shown to prevent cardiovascular disease.
The label excerpts specify indications to reduce risks of myocardial infarction, stroke, and revascularization/angina/hospitalization for CHF in defined populations; 'prevent cardiovascular disease' is broader than the label wording in 1.1.
Lipitor has been shown to lower blood pressure in patients with hypertension.
No claim about blood pressure lowering is present in the provided label excerpts.
Lipitor can cause liver damage, including elevated liver enzymes and liver failure.
The label excerpts discuss biochemical abnormalities of liver function tests, persistent transaminase elevations, monitoring, and contraindication in active liver disease/unexplained persistent transaminase elevations; they do not explicitly state 'liver failure.'
Lipitor can increase the risk of developing diabetes.
No diabetes risk statement is present in the provided label excerpts.
Taking Lipitor with cyclosporine can increase the risk of kidney damage.
The provided label excerpts state cyclosporine can increase atorvastatin bioavailability and requires limiting atorvastatin dose; they do not mention kidney damage.
Contradictions
Important Omissions
If the audit were possible, major label safety elements that are not included in the claim list (e.g., contraindications beyond active liver disease/persistent transaminase elevations, specific boxed warning content if any, and the recommended monitoring schedule and thresholds for liver enzymes and muscle effects) would be evaluated for omissions if the AI response contained any such discussion.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Because the audit cannot be performed against the actual AI response text, safety risk is assessed as low for label-alignment verification rather than for clinical risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Evaluatable
Primary Issue
No actual AI-generated response text was provided to audit; only a list of claims appears separate from an AI response. As a result, alignment cannot be reliably determined end-to-end.
Suggested Improvement
Provide the exact AI-generated response text you want audited (verbatim), then the tool can map each sentence to the provided label excerpts and score alignment accurately.